{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-037180","form_type":"8-K","ticker":"ESPR","cik":"0001434868","company_name":"Esperion Therapeutics, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.071543+00:00","generated_at":"2026-06-08T14:30:09.859339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Esperion Q3 total revenue $34M (+79% YoY); FDA PDUFA date March 31, 2024","bullets":["Q3 total revenue $34.0M (+79% YoY); U.S. product revenue $20.3M (+45% YoY).","Net loss $41.3M ($0.37 per share) vs $55.1M ($0.81) in prior year.","FDA accepted sNDA for expanded CV risk reduction label; PDUFA date March 31, 2024.","Cash $114.8M at Sep 30 vs $166.9M at Dec 31; FY 2023 OpEx guidance $225-245M.","Presented CLEAR Outcomes analyses at ESC showing 20% reduction in total MACE."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-037180","json":"https://secwatch.observer/filing/0001628280-23-037180.json","markdown":"https://secwatch.observer/filing/0001628280-23-037180.md","text":"https://secwatch.observer/filing/0001628280-23-037180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/0001628280-23-037180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/espr-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T14:30:09.859339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eb89170c9565bd45be88089ee2628052d88f81c9","claim":"Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2023 results: revenue $34.0 million, net income $41.3 million, EPS $0.37.","evidence_excerpt":"--- EX-99.1 (EX-99.1) --- Esperion Reports Third Quarter 2023 Financial Results – Q3 U.S. Net Product Revenue Grew 45% Y/Y to $20.3 Million; Q3 Total Revenue Grew 79% Y/Y to $34.0 Million – – Q3 Retail Prescription Equivalents Grew 33% Y/Y and 8% Q/Q, Demonstrating Sustained Momentum into 2H 2023 – – Received FDA Acceptance of Application for Expanded CV Risk","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434868/000162828023037180/0001628280-23-037180-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$34.0 million"},{"label":"Net income","value":"$41.3 million"},{"label":"EPS","value":"$0.37"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}